Abstract: A semiconductor memory device includes a substrate including a cell region, a core region, and a boundary region between the cell region and the core region, a boundary element isolation layer in the boundary region, the boundary element isolation layer being in a boundary element isolation recess and including first and second boundary liner layers extending along a profile of the boundary element isolation recess and a first gate structure on the core region and at least a part of the boundary element isolation layer, wherein the first gate structure includes a first high dielectric layer, and a first gate insulating pattern below the first high dielectric layer, with a top surface of the substrate being a base reference level, the first gate insulating pattern does not overlap a top surface of the first boundary liner layer, and wherein the first gate insulating pattern includes a first_1 gate insulating pattern between a top surface of the second boundary liner layer and a bottom surface of the first high

Abstract: The present invention relates to a chemical and biological integrated degradation process for PET, for recycling PET, and, more specifically, the present invention provides a PET upcycling technique for producing a high-value product via a chemical pretreatment process of PET, a TPA and EG production process using an enzyme, and a process for converting TPA and EG to PCA and GLA, respectively.

Abstract: The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11?-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11?-HSD1 (11?-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11?-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

Abstract: The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11?-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11?-HSD1 (11?-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11?-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

Abstract: The present invention relates to a novel use of herbal extracts in a pharmaceutical composition for prevention and treatment of nephritis and, more particularly, to a pharmaceutical composition and a health functional food for prevention and/or treatment of nephritis that contains at least one herbal extract selected from the group consisting of a Crataegi Fructus extract, a Cinnamomi Cortex extract, a Prunella Spica extract, and an Equiseti Herba extract, a method for prevention and/or treatment of nephritis using the herbal extract, and a use of the herbal extract in preparation of a composition for prevention and/or treatment of nephritis. The herbal extract has a good therapeutic effect for nephritis on a nephritis model of which the nephritis is induced by a drug such as gentamicin, cisplatin, etc., and a good inhibitory activity on the growth of mesangial cells in kidneys, thereby providing a very useful means for prevention and/or treatment of nephritis.

Abstract: The present invention relates to a novel use of herbal extracts in a pharmaceutical composition for prevention and treatment of nephritis and, more particularly, to a pharmaceutical composition and a health functional food for prevention and/or treatment of nephritis that contains at least one herbal extract selected from the group consisting of a Crataegi Fructus extract, a Cinnamomi Cortex extract, a Prunella Spica extract, and an Equiseti Herba extract, a method for prevention and/or treatment of nephritis using the herbal extract, and a use of the herbal extract in preparation of a composition for prevention and/or treatment of nephritis. The herbal extract has a good therapeutic effect for nephritis on a nephritis model of which the nephritis is induced by a drug such as gentamicin, cisplatin, etc., and a good inhibitory activity on the growth of mesangial cells in kidneys, thereby providing a very useful means for prevention and/or treatment of nephritis.